Drug profile · INN
lecanemab-irmb
LEQEMBI
lecanemab-irmb (LEQEMBI) is a amyloid-beta a4 protein inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — lecanemab-irmb
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lecanemab-irmb (LEQEMBI) is a amyloid-beta a4 protein inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Amyloid-beta A4 protein inhibitor
Primary target: Amyloid-beta precursor protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
Eisai's Leqembi Sales Forecast: A Turning Point?
Structured plan for Eisai's Leqembi Sales Forecast: A Turning Point?
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
Eisai projects significant growth for its Alzheimer's treatment, Leqembi, with sales forecasts indicating a strong path toward blockbuster status. This analysis explores the drivers behind this projection and its strategic implications for the pharmaceutical industry.
Eisai's Leqembi Sales Forecast: A Closer Look at $900M Potential
Eisai is making strides toward achieving blockbuster status for Leqembi, with a projected sales forecast of $900M. This article explores the implications for the pharmaceutical landscape.
Related & competitor drugs
Frequently asked questions
What is lecanemab-irmb?
lecanemab-irmb (LEQEMBI) is a amyloid-beta a4 protein inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for lecanemab-irmb?
LEQEMBI is a marketed brand name for lecanemab-irmb. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lecanemab-irmb?
lecanemab-irmb has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.